博瑞医药BGM1812注射液获美国FDA药品临床试验批准

Core Viewpoint - The company, Bory Pharmaceutical, has received FDA approval to initiate Phase I clinical trials for BGM1812 injection, aimed at treating overweight or obesity [1] Company Summary - BGM1812 injection is a newly designed long-acting Amylin analog with good molecular activity and pharmaceutical stability [1] - Amylin is a 37-amino acid peptide hormone that promotes satiety and is co-released with insulin from pancreatic beta cells [1] Mechanism of Action - The drug activates brain pathways that induce feelings of fullness, suppresses appetite, delays gastric emptying, and inhibits glucagon secretion, contributing to its weight loss effects [1]